However, the clusters 1 and 3 were characterized by the mutations of IDH1, TP53, and TTN. IDH1 and ATRX mutants were chosen to be studied for their inclusion in the current WHO glioma classification. This evidence concerns the gene TTN and central nervous system cancer.